8-K: Outlook Therapeutics Achieves EU and UK Approval for Wet AMD Treatment, Advances Clinical Trial

Outlook Therapeutics reports positive financial results for Q3 2024, highlighted by EU and UK marketing authorization for LYTENAVA and progress in the NORSE EIGHT clinical trial.

Summary

• Outlook Therapeutics announced its financial results for the third fiscal quarter ended June 30, 2024, reporting a net income of $44.4 million, or $1.91 per basic share, and a net loss of $0.89 per diluted share.
• The company also reported an adjusted net loss of $19.2 million, or $0.83 per basic and diluted share, for the same period.
• Key achievements include the receipt of marketing authorization for LYTENAVA in the European Union and the United Kingdom for the treatment of wet age-related macular degeneration (wet AMD).
• The NORSE EIGHT clinical trial is progressing with 359 subjects enrolled as of the date of the release, and full enrollment is expected in Q3 CY2024.
• Topline results from the NORSE EIGHT trial are anticipated in Q4 CY2024, with a planned resubmission of the ONS-5010 Biologics License Application (BLA) in Q1 CY2025.
• The company is preparing for commercial launches of LYTENAVA in Europe, expected to commence in the first half of calendar year 2025.
• Outlook Therapeutics has a strategic collaboration with Cencora to support the global commercial launch of LYTENAVA.
• The company closed private placements of common stock and warrants in March and April 2024, raising $65 million upfront with the potential for an additional $107 million upon full exercise of warrants.
• As of June 30, 2024, the company had $32.0 million in cash and cash equivalents.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the regulatory approvals in the EU and UK, progress in clinical trials, and successful capital raising. However, the adjusted net loss and ongoing need for funding temper the overall optimism.

Positives

• The company achieved marketing authorization for LYTENAVA in both the EU and UK, marking a significant regulatory milestone.
• The NORSE EIGHT clinical trial is progressing well, with enrollment on track and topline results expected soon.
• The company has a clear timeline for the resubmission of the ONS-5010 BLA and commercial launch in Europe.
• The strategic collaboration with Cencora provides strong support for the global commercial launch of LYTENAVA.
• The company has secured significant funding through private placements, strengthening its financial position.
• The company reported a net income of $44.4 million for the quarter, although this was largely due to non-cash accounting adjustments.

Negatives

• The company reported an adjusted net loss of $19.2 million for the third fiscal quarter of 2024.
• The company's cash and cash equivalents stand at $32.0 million, which may require further capital raising in the future.
• The company is still awaiting FDA approval for ONS-5010 in the US, which is not expected until the second half of CY2025.

Risks

• The company faces risks associated with developing and commercializing pharmaceutical product candidates.
• There are risks in conducting clinical trials and obtaining necessary regulatory approvals.
• The company's financial resources may not be sufficient to support all planned activities.
• The company is subject to market conditions and macroeconomic factors, including overseas conflicts, high interest rates, and inflation.
• There is uncertainty regarding the timing and outcome of regulatory decisions.

Future Outlook

The company anticipates full enrollment of the NORSE EIGHT clinical trial in Q3 CY2024, topline results in Q4 CY2024, resubmission of the ONS-5010 BLA in Q1 CY2025, and initial commercial launches in Europe in the first half of CY2025, with potential for US FDA approval in the second half of CY2025.

Management Comments

• Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, stated that the company achieved two major milestones with receipt of Marketing Authorization in both the European Union and the United Kingdom.
• Russell Trenary also noted that the company made significant progress with the NORSE EIGHT clinical trial and expects to report results in the fourth calendar quarter of 2024.

Industry Context

The approval of LYTENAVA in the EU and UK positions Outlook Therapeutics as a key player in the wet AMD treatment market, offering the first authorized ophthalmic formulation of bevacizumab. This development is significant as it provides an alternative to existing treatments and could potentially capture a substantial market share. The company's strategic collaboration with Cencora further strengthens its position for a successful commercial launch.

Comparison to Industry Standards

• The approval of LYTENAVA in the EU and UK is a significant achievement, as it is the first authorized ophthalmic formulation of bevacizumab for wet AMD, setting it apart from competitors like Roche's Lucentis (ranibizumab) and Regeneron's Eylea (aflibercept), which are not bevacizumab formulations.
• The NORSE EIGHT trial is designed as a non-inferiority study comparing ONS-5010 to ranibizumab, a common benchmark in wet AMD treatment trials. Success in this trial would be a major step towards FDA approval in the US.
• The company's collaboration with Cencora for commercial launch support is similar to strategies employed by other pharmaceutical companies to ensure efficient market access and distribution.
• The financial results, while showing a net income due to accounting adjustments, also highlight the ongoing costs associated with clinical trials and regulatory processes, which is typical for companies in this stage of development.

Stakeholder Impact

• Shareholders will be impacted by the positive regulatory news and the potential for future revenue from LYTENAVA.
• Employees may benefit from the company's growth and expansion.
• Patients with wet AMD in the EU and UK will have access to a new treatment option.
• The collaboration with Cencora will impact suppliers and distributors in the pharmaceutical supply chain.

Next Steps

• Full enrollment of the NORSE EIGHT clinical trial is expected in Q3 CY2024.
• Topline results from the NORSE EIGHT clinical trial are planned for Q4 CY2024.
• The resubmission of the ONS-5010 BLA is targeted for Q1 CY2025.
• Initial commercial launches in Europe are planned to commence in the first half of CY2025.
• The company is assessing partnering options for LYTENAVA in the EU and the UK and other regions outside of the US.

Key Dates

Keywords

LYTENAVA, ONS-5010, wet AMD, bevacizumab, clinical trial, NORSE EIGHT, FDA, BLA, EU, UK, marketing authorization, biopharmaceutical, retina, Cencora, commercial launch